Company Overview
Development and commercialisation of its intellectual property which allows for specialised surfaces which can be used in energy and in vitro diagnostic markets.
Website | anteotech.com |
---|---|
Head Office | Eight Mile Plains QLD |
Registry | Link Market Services |
CEO | David Radford |
Chair Person | Ewen Crouch |
GICS Industry | Pharmaceuticals, Biotechnology & Life Sciences |
Sub Industry | Life Sciences Tools & Services |
Sector | Health Care |
Market Cap | $96 m |
---|---|
Shares on Issue | 1,99 b |
Status | Trading |
Last Price | |
Change | |
52 Week H/L | |
VWAP | |
Bid/Ask |
Directors and Management
Dr Katherine Leslie Woodthorpe
Non-Executive Director 01/09/2021
Dr Woodthorpe is an experienced Chair and Non-Executive Director serving for 20 years on the boards of a range of organizations including listed entities, government boards and for purpose organizations. She has experience working in a range of innovation-dependent industries including healthcare, renewable energy and environmental and climate science. Katherine also has knowledge of the private equity and venture capital industries in the financial sector as well as working closely with superannuation funds on their alternative investments in the private equity space. For seven years she was the Chief Executive of AVCAL, the Australian Private Equity and Venture Capital Association. Prior to AVCAL, she held a range of management and board positions, in Australia and overseas. Katherine commenced her career initially as a chemist then moved to sales of specialised laboratory equipment into the medical and oil, gas and petrochemical sectors covering the geographies of Europe, Asia and the Middle East before locating permanently to Australia in 1988. Dr Woodthorpe, amongst several positions, is a Non-Executive Director of the Olivia Newton John Cancer Research Institute, Bioplatforms Australia Ltd and Vast Solar Pty Ltd.
AO, BSc, PhD(Chem), FAICD, FTSE, Female
Dr Geoffrey James Cumming
Non-Executive Director 02/04/2009
Dr Cumming has over 20 years experience in the healthcare and biotechnology market. His roles have progressed from pure research to sales and marketing roles through to Managing Director level and Board seats. Previously Managing Director of Roche Diagnostic Systems - Oceania Regional Centre, where he transformed a loss making business to one achieving over 30% compound annual growth over a four year period and the highest profitability levels in Roches global organisation. He was also Managing Director and CEO of an Australian based biotechnology company commercialising a range of products in cancer diagnosis and treatment. During his tenure he was responsible for taking research from Sydney University through to product registration. This involved capital raising, managing Intellectual Property, investor relations and forging links with relevant international partners. Geoffrey is a Non-Executive Director of Multiple Sclerosis Research Australia, a not-for profit organisation.
BAppSc, BSc.(Hons.),MBA, PhD, MAICD Male
Dr John (Jack) Andrew Hamilton
Non-Executive Chairman,Non-Executive Director 01/04/2018
Dr Hamilton's career spans over 30 years in the energy sector. He has held senior positions across the energy sector over the past 15 years including heading up Australia's largest resource project as Director North West Shelf Ventures for Woodside Energy Ltd, CEO for a Liquid Natural Gas project in PNG following on from a 21 year career with Shell in both local and international roles. His career gained experience across a range of functions including, strategy development, commercial marketing, mergers/acquisitions, capital raisings, manufacturing operations and project management in the energy and petrochemical sectors. Jack is currently a Non-Executive Director with Calix Ltd. He formerly held directorships with DUET Group Ltd, Southern Cross Electrical Engineering Ltd, Federation Training and chair of Renu Energy Ltd and Antilles Oil and Gas NL. He is member of the Risk Committee.
BE(Chem), Dphill, FAIE, FAICD Male
Ms Glenda McLoughlin
Non-Executive Director 01/09/2021
Ms McLaughlin is an experienced Non-Executive Director with over 25 years' experience as an Investment Banker and Senior Executive working in Australia, Asia, the UK and the US. She has held senior executive roles at leading financial institutions Morgan Stanley, Credit Suisse and Barclays Capital where she led the Energy and Infrastructure Group in Australia. In addition to her work in the energy sector, Glenda has experience in the medical diagnostics, telecommunications, information technology, media, transport and financial services sectors. Glenda co-founded listed Australian gas company Metgasco Ltd, where she was Executive Director and Chief Financial Officer for eight years. Ms McLoughlin currently holds the positions of Non-Executive Director with Senex Energy Ltd where she chairs the Audit and Risk Committee and is Chair of SCEGGS Redlands. Ms McLoughlin will also Chair of AnteoTech's Risk Committee.
BEco, MBA, FAICD Female
Mr Richard Shubrick Martin
Non-Executive Director 23/09/2005
Mr Martin holds a Bachelor of Business. He practised as a Chartered Accountant for 16 years, 11 as a partner in a medium sized Sydney practice. Mr Martin has been involved with the Company since it was founded by Dr Maeji. He has considerable experience both operationally and advising corporate entities, his work has included complex business structuring and financing, the establishment of international hotels from conception, public listing of companies, management of foreign currency exposure, establishing and operating start up technology companies and the negotiation and implementation on the purchase and sale of enterprises.
B.Bus Chartered Accountant Male
Mr Christopher Parker
Non-Executive Director 23/04/2019
Mr Parker has over 30 years of experience in both domestic and international life sciences sectors predominately through a career with Roche Diagnostics, an internationally renowned pharmaceutical and diagnostics company. In his final role with Roche, before retiring in the second half 2017, he was Managing Director for UK & Ireland and Management Centre European Agents. Prior to this he held various roles in general management, marketing and business development in Canada, Asia and Australia targeting the centralised laboratory, decentralised point-of-care (POC), molecular diagnostics and applied sciences markets. He is a member of Risk Committee.
BAppSc (QUT),Grad Dip ? Marketing (UTS) Male
Top 20 Shareholders
Name | Shares | % | |
---|---|---|---|
1. | Levenson Investments Pty Ltd <Levenson Investment A/C> | 109,315,332 | 5.55 |
2. | First Cape Management Pty Ltd | 55,346,154 | 2.81 |
3. | Marcolongo Nominees Pty Ltd <Marcolongo Super Fund A/C> | 53,439,928 | 2.71 |
4. | Addison Lake Quality Hire Pty Limited | 33,048,603 | 1.68 |
5. | Fossil Super Pty Ltd <Fossil Fund A/C> | 32,459,231 | 1.65 |
6. | Jackjen Pty Ltd <J A Hamilton Super Fund A/C> | 30,018,593 | 1.52 |
7. | Bond Street Custodians Limited <Antsm1 - D67076 A/C> | 29,130,249 | 1.48 |
8. | Computer Visions Pty Ltd <Visionary Invests S/F A/C> | 22,132,994 | 1.12 |
9. | BNP Paribas Nominees Pty Ltd <IB AU Noms Retailclient DRP> | 21,599,216 | 1.10 |
10. | Mr Derek Thomson | 21,580,554 | 1.10 |
11. | Marcolongo Nominees Pty Ltd <Marcolongo Family A/C> | 20,134,578 | 1.02 |
12. | Mrs Mary Curtis | 18,120,900 | 0.92 |
13. | Mr Peter Frederick Kemmis | 17,198,314 | 0.87 |
14. | Citicorp Nominees Pty Limited | 17,083,422 | 0.87 |
15. | Awo & Cao Investments Pty Ltd <Awo & Cao Family S/F A/C> | 15,983,571 | 0.81 |
16. | Stydon Capital Pty Ltd | 15,536,780 | 0.79 |
17. | Terry & Linden Deavin Super Pty Ltd <T & L Deavin Sf A/C> | 14,600,000 | 0.74 |
18. | Austcorp No 190 Pty Ltd | 14,381,945 | 0.73 |
19. | Mr Anthony William Olding & Mrs Caroline Anne Olding | 14,091,375 | 0.72 |
20. | Mr Philip Michael Deavin & Mrs Chimene Maree Deavin | 13,260,000 | 0.67 |
Director Transactions
Date | Name | Qty | Value | Direction | Notes |
---|---|---|---|---|---|
17/09/2021 | Glenda McLoughlin | 250,000 | $58,750 | Buy | On-market trade. |
02/08/2021 | Geoffrey Cumming | 500,000 | $112,500 | Sell | On-market trade. |
25/05/2021 | Christopher Parker | 17,369 | $4,515 | Sell | As advised by the company. Withdrawal of SPP application (at $0.26 per share) |
25/05/2021 | Christopher Parker | 17,369 | $4,515 | Buy | Participation in share purchase plan. |
25/05/2021 | Geoffrey Cumming | 17,369 | $4,515 | Buy | Participation in share purchase plan. |
25/05/2021 | Geoffrey Cumming | 17,369 | $4,515 | Sell | As advised by the company. Withdrawal of SPP application (at $0.26 per share) |
25/05/2021 | John (Jack) Hamilton | 24,069 | $6,257 | Sell | As advised by the company. Withdrawal of SPP application (at $0.26 per share) |
25/05/2021 | John (Jack) Hamilton | 24,069 | $6,257 | Buy | Participation in share purchase plan. |
27/11/2020 | Geoffrey Cumming | 1,289,013 | $128,901 | Sell | On-market trade. |
23/11/2020 | Matthew (Matt) Sanderson | 2,628,450 | $52,569 | Buy | Exercise of options. |
23/11/2020 | Matthew (Matt) Sanderson | 2,628,450 | $52,569 | Exercise | Exercise of options. |
16/11/2020 | John (Jack) Hamilton | 5,886,818 | $117,736 | Exercise | Exercise of options. |
16/11/2020 | John (Jack) Hamilton | 2,400,000 | $216,000 | Issued | Issue of options. |
16/11/2020 | John (Jack) Hamilton | 5,886,818 | $117,736 | Issued | Exercise of options. |
12/11/2020 | Geoffrey Cumming | 1,500,000 | $127,500 | Issued | Issue of options. |
12/11/2020 | Matthew (Matt) Sanderson | 1,500,000 | $127,500 | Issued | Issue of options. |
12/11/2020 | Christopher Parker | 1,500,000 | $127,500 | Issued | Issue of options. |